Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GTB 3650

Next Previous
Drug Profile

GTB 3650

Alternative Names: Anti-CD16-IL-15-anti-CD33 TriKE; GTB-3650; OXS-C3550; OXS-C3550 TriKE

Latest Information Update: 05 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Minnesota
  • Developer GT Biopharma; University of Minnesota
  • Class Antineoplastics; Immunoglobulin Fv fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 19 Nov 2024 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV), (NCT06594445),
  • 19 Nov 2024 Phase-I clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in USA (IV), (NCT06594445),
  • 01 Oct 2024 Masonic Cancer Center, University of Minnesota plans a phase I trial for Acute myeloid leukemia and Myelodysplastic syndromes (Second-line therapy or greater) (Parenteral, Infusion) (NCT06594445)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top